Dr Reddy’s Laboratories has announced the launch of Nerivio, a wearable therapy device approved by the US Food and Drug Administration (USFDA) for treating migraines without the use of drugs.
Migraines are a major health issue globally, affecting about 30% of adults for at least 15 days each month. In India alone, migraines impact 1.7 to 4% of the population, with women making up approximately 60% of the 213 million sufferers.
Nerivio is a prescription-based, non-invasive device designed to treat migraines in both adults and adolescents aged 12 years and older. The device is worn on the upper arm and should be used within 60 minutes of the onset of a headache for acute treatment, or every other day for prevention.
The device uses a mechanism called Remote Electrical Neuromodulation (REN) to stimulate nerve endings and activate conditioned pain modulation. This triggers a natural pain-relieving process in the brainstem, providing relief from migraine pain.
According to MV Ramana, the CEO of Branded Markets at Dr Reddy’s, Nerivio is the first USFDA-approved, drug-free, non-invasive product for migraine treatment in India. It offers a safe alternative for migraine patients and meets a genuine clinical need.
The launch of Nerivio represents Dr Reddy’s entry into digital therapeutics, a field gaining popularity among physicians and patients due to its potential to reduce reliance on medication for chronic or difficult-to-treat conditions.
Nerivio is clinically proven to be safe and suitable for a wide range of patients, including those who prefer drug-free options, individuals who cannot tolerate medications or have contraindications, adolescents, women of vulnerable age groups, and patients at risk of medication overuse headaches.
